Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : NVS crawled date : 2022 - 06 - 06 save search
Lupus Nephritis Market to Extend at a CAGR of 8.4% by 2032 | DelveInsight
Published: 2022-06-06 (Crawled : 16:00) - prnewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: -1.87%
H: 2.91%
C: 2.91%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: -1.04%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 3.83%
H: 0.0%
C: 0.0%
OMER | $3.04 -1.62% -1.64% 250K
|
Health Technology
|
| O: 0.8%
H: 2.78%
C: -13.1%
lupus market
Third Harmonic Bio Appoints Edward R. Conner, M.D., as Chief Medical Officer
Published: 2022-06-06 (Crawled : 13:00) - biospace.com/
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: -1.87%
H: 2.91%
C: 2.91%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: -1.04%
Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study
Published: 2022-06-06 (Crawled : 12:20) - prnewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: -1.87%
H: 2.91%
C: 2.91%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.31%
H: 0.0%
C: -1.04%
tafinlar novartis
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.